Analyst Ratings for [IQV] IQVIA Holdings Inc.

2/3/25	Downgrades	Buy Neutral	X
IQV IQVIA BTIG Research
12/20/24	Initiated	Overweight	X
IQV IQVIA Stephens
$250
10/14/24	Initiated	Buy	X
IQV IQVIA Redburn Atlantic
9/4/24	Initiated	Outperform	X
IQV IQVIA RBC Capital Mkts
$275
7/24/24	Downgrades	Buy Hold	X
IQV IQVIA Jefferies
$266 $242
6/6/24	Initiated	Buy	X
IQV IQVIA Goldman
$270
2/26/24	Initiated	Outperform	X
IQV IQVIA Leerink Partners
$290
2/15/24	Downgrades	Buy Neutral	X
IQV IQVIA Guggenheim
2/13/24	Initiated	Buy	X
IQV IQVIA BTIG Research
$285
11/2/23	Downgrades	Outperform Neutral	X
IQV IQVIA Robert W. Baird
$248 $202
9/6/23	Initiated	Buy	X
IQV IQVIA HSBC Securities
$260
3/17/23	Initiated	Buy	X
IQV IQVIA Truist
$265
12/6/22	Initiated	Outperform	X
IQV IQVIA Cowen
$251
11/17/22	Downgrades	Buy Neutral	X
IQV IQVIA Citigroup
$275 $245
8/25/22	Initiated	Outperform	X
IQV IQVIA Credit Suisse
$300
7/15/22	Initiated	Outperform	X
IQV IQVIA SVB Leerink
$256
5/24/22	Initiated	Buy	X
IQV IQVIA Guggenheim
$244
4/29/22	Upgrades	Neutral Overweight	X
IQV IQVIA Piper Sandler
$231 $255
4/25/22	Downgrades	Overweight Eq Weight	X
IQV IQVIA Wells Fargo
$235
4/16/21	Upgrades	Eq-Weight Overweight	X
IQV IQVIA Stephens
$180 $250
3/8/21	Upgrades	Sec Weight Overweight	X
IQV IQVIA KeyBanc Capital Markets
$218
3/3/21	Initiated	Overweight	X
IQV IQVIA Barclays
$220
6/21/19	Upgrades	Neutral Buy	X
IQV IQVIA Mizuho
$150 $175
5/28/19	Initiated	Outperform	X
IQV IQVIA SVB Leerink
1/18/19	Upgrades	Hold Buy	X
IQV IQVIA Jefferies
10/9/18	Initiated	Buy	X
IQV IQVIA UBS
10/2/18	Reiterated	Outperform	X
IQV IQVIA Robert W. Baird
$143 $146
7/25/18	Upgrades	Neutral Buy	X
IQV IQVIA BofA/Merrill
7/25/18	Reiterated	Buy	X
IQV IQVIA Stifel
$128 $150
7/3/18	Upgrades	Outperform Strong Buy	X
IQV IQVIA Raymond James
4/13/18	Upgrades	Neutral Buy	X
IQV IQVIA Goldman
3/7/18	Upgrades	Hold Buy	X
IQV IQVIA SunTrust

IQV IQVIA Holdings Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.